neurovascular-nuggets’ Post

🔬 Advancing Knee Pain Treatment Through Innovation and Research 🦵 At IR Centers, we are committed to pushing the boundaries of minimally invasive treatments through cutting-edge research and clinical trials. Recently, our team conducted a Pre-Clinical lab project to study novel embolic agents in the treatment of knee pain using genicular artery embolization (GAE). This preclinical research sets the stage for advancing patient care and outcomes. IR Centers’ physicians have been trailblazers in this field, having led the first clinical trial in the United States and the first randomized clinical trial for genicular artery embolization. These significant milestones highlight our dedication to bringing innovative, evidence-based treatments to patients. “Continued research, innovation, and development are at the core of IR Centers’ mission to improve patient care,” said Dr. Ari Isaacson, Chair of Research and Quality at IR Centers Ari Isaacson “By advancing novel embolic agents and refining techniques like genicular artery embolization, we aim to provide patients with more effective, less invasive options for managing chronic knee pain.” Why This Matters for Patients: When new, promising treatments are brought to market, it’s critical to work with leading providers who are pioneering the research and mastering these advanced techniques. The expertise gained through clinical trials and animal lab studies enables our physicians to deliver safer, more predictable outcomes for patients struggling with knee pain. As we continue to lead research efforts in genicular artery embolization, our mission remains clear: to provide innovative, minimally invasive solutions that enhance the quality of life for our patients. 📸 Stay tuned for continued advancements of the GAE procedure to see how we are invested in making a difference in the field of interventional radiology. #InnovationInHealthcare #ClinicalTrials #KneePain #Embolization #PatientCare #ResearchAndQuality #IRCenters #MinimallyInvasive #LeadingProviders #InterventionalRadiology Ari Isaacson Alex Pavidapha Prostate Centers USA Marco Mastrangelo Tiffany Ramos Lauren Richards Society of Interventional Radiology

HistoSonics, Inc. in Practical Patient Care: HistoSonics has announced the treatment of the first patients with pancreatic tumours in the GANNON trial using its Edison Histotripsy System. The trial evaluates the safety of #histotripsy, a non-invasive technology that uses focused ultrasound to target and destroy tumour tissue. The GANNON feasibility study will include up to 30 patients with inoperable pancreatic adenocarcinoma, either locally advanced (Stage 3) or with limited spread to other areas (Stage 4). Read the article: https://lnkd.in/e47ZiaMP

❤️🧲 The study evaluates mitral valve orifice area as a predictor of outcomes following biventricularrepair in patients with hypoplastic left ventricles (HLV). Conducted at Boston Children’sHospital, this single-center retrospective analysisinvolved 122 patients with HLV whounderwent biventricular repair between 2005 and 2022. The focus was on preoperativecardiovascular magnetic resonance (CMR) measurements of the mitral valve (MV) orifice areaduring diastole.Key findings include: 1.The study identified a low MV orifice area and pre-existing MV pathology as significant risk factors for adverse outcomes post-biventricular repair. 2. Primary composite outcomes were analyzed, including death, transplant, biventriculartakedown, heart failure admission, left atrial decompression, or unexpected reoperation. 3. The median follow-up was 0.7 years, with a primary outcome freedom rate of 53% foratrioventricular canal (AVC) patients and 69% for non-AVC at two years. 4. Secondary outcomes focused on ≥ moderatemitral stenosis or regurgitation, showing afreedom rate of 49% for AVC and 79% for non-AVC at two years. 5. Independent predictors of adverse primary outcomes included MV orifice area z-score <-2, transitional AVC for AVC patients, and abnormal MV anatomyand conal-septalventricular septal defect for non-AVC patients.This study highlights the critical role of MV orifice area in predicting outcomes in HLV patientsundergoing biventricular repair, suggesting that detailed preoperative CMR evaluation of theMVis essential for optimal surgical planning and risk assessment. Dr. Liddle explains below. Full text available here 👉 https://lnkd.in/g8ZDPA6K

📢 Just out in CardioVascular and Interventional Radiology (CVIR): New insights on the treatment of hepatic hemangiomas (HHs) using transcatheter arterial embolization (TAE) with bleomycin-Lipiodol & gelatin sponge particles! 🩺💉 Explore the impact on HH treatment. 🧠 Study Focus: • Retrospective analysis across 3 centers from 2014 to 2021 • 102 patients with 109 HHs examined • Assessment of TAE's effectiveness and safety • Analysis of CT changes post-TAE 🔬 Core Results: • Significant tumor reduction post-TAE (diameter: 8.5 cm to 5.9 cm, volume: 412.6 cm³ to 102.0 cm³, both P < 0.001) • 80.7% (88/109) tumors achieved 50% volume reduction • Sustained Lipiodol retention noted within shrinking tumors over time 🧩 Key Predictors of TAE Response: • Atypical enhancement (tiny dots on CT): P = 0.001 • Central arterioportal shunt (APS) within tumor: P = 0.002 • Both associated with lower success rates of TAE effectivity 🛡️ Safety Profile: • Postembolization syndrome and transient liver enzyme increase were common • No severe complications or death reported 📌 Conclusion: TAE proves to be a safe and effective method for reducing the size of HHs. Notably, the lesion enhancement pattern and APS are crucial in predicting TAE's efficacy. Dive into the full paper: https://lnkd.in/gBk9xdHv Shoutout to the researchers behind this study! 👏 What's your experience with TAE for HH? Could these findings change your protocol? Stay ahead in the latest vascular interventions. Join our community for updates: https://lnkd.in/gRwAjsEf #VIR #iRads #Radiology #InterventionalRadiology #HepaticHemangioma #PatientSafety #LiverHealth #Embolization #MedEd #Oncology #Healthcare

Irreversible Electroporation (IRE) as a Valid Treatment Option for Hepatic Epithelioid Hemangioendothelioma We are grateful to Dr. Raj Narayanan and his coauthors for this important retrospective study of IRE as a treatment option for hepatic EHE (HEHE). Patients and clinicians have been eager to learn more about the outcomes of this treatment and this research provides an excellent foundation for future investigation. What does this mean for patients? In this small cohort study of IRE for #HEHE, patients can better understand the benefits of IRE and its potential effectiveness. Advantages highlighted in this study such as post-treatment healing, the opportunity to have repeated procedures, and importantly, the ability to treat tumors near critical blood vessels give evidence supporting IRE as a viable treatment consideration for HEHE. We look forward to future prospective studies of IRE in HEHE that can expand on this research, hopefully adding a very effective ‘tool’ in the hepatic EHE treatment toolbox. Read the full article published earlier this month in CardioVascular and Interventional Radiology. https://lnkd.in/e88RPtq4 #EHE #epithelioidhemangioendothelioma #ultrararesarcoma #EHEFoundation #theEHEFoundation #EHEcancer #justlive #sarcoma #raredisease #EHEresearch #EHEawareness

📃Scientific paper: Aneurysm Treatment with Woven EndoBridge-17: Angiographic and Clinical Results at 12 Months from a Retrospective, 2-Center Series Abstract: BACKGROUND AND PURPOSE: This retrospective, 2-center study investigated the feasibility, safety, and efficacy at 12-month follow-up of the treatment of ruptured, unruptured, and recurrent intracranial aneurysms using the latest generation of the Woven EndoBridge (WEB) device, the WEB-17 system. MATERIALS AND METHODS: Aneurysms treated with WEB-17 were extracted from the databases of 2 neurovascular centers. Patients, aneurysm characteristics, complications, and clinical and anatomic results were analyzed. RESULTS: From February 2017 to May 2021, two hundred twelve patients with 233 aneurysms (181/233, 77.7%, unruptured-recurrent, and 52/233, 22.3%, ruptured) were included. High treatment feasibility (95.3%) was reported and was similar in ruptured aneurysms (94.2%) and unruptured-recurrent aneurysms (95.6%) (P = .71) and in typical (95.4%) and atypical (94.7%) locations (P = .70), but it was lower in aneurysms with an angle between the parent artery and main aneurysm axis of ≥45° (90.2%) compared with those with an angle of <45° (97.1%) (P = .03). Global mortality and morbidity were 1.9% and 3.8% at 1 month, respectively, and 4.4% and 1.9% at 12 months, respectively. One-month morbidity (P = .02) and mortality (P = .003) were higher in the ruptured group (10.0% and 8.0%, respectively) compared with unruptured-recurrent group (1.9% and 0.0%, respectively). Overall adequate occlusion (complete occlusion and neck remnant) was 86.3%. The percentage of adequate occlusion... Continued on ES/IODE ➡️ https://etcse.fr/ZMOGt ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Aneurysm Treatment with Woven EndoBridge-17: Angiographic and Clinical Results at 12 Months from a Retrospective, 2-Center Series Abstract: BACKGROUND AND PURPOSE: This retrospective, 2-center study investigated the feasibility, safety, and efficacy at 12-month follow-up of the treatment of ruptured, unruptured, and recurrent intracranial aneurysms using the latest generation of the Woven EndoBridge (WEB) device, the WEB-17 system. MATERIALS AND METHODS: Aneurysms treated with WEB-17 were extracted from the databases of 2 neurovascular centers. Patients, aneurysm characteristics, complications, and clinical and anatomic results were analyzed. RESULTS: From February 2017 to May 2021, two hundred twelve patients with 233 aneurysms (181/233, 77.7%, unruptured-recurrent, and 52/233, 22.3%, ruptured) were included. High treatment feasibility (95.3%) was reported and was similar in ruptured aneurysms (94.2%) and unruptured-recurrent aneurysms (95.6%) (P = .71) and in typical (95.4%) and atypical (94.7%) locations (P = .70), but it was lower in aneurysms with an angle between the parent artery and main aneurysm axis of ≥45° (90.2%) compared with those with an angle of <45° (97.1%) (P = .03). Global mortality and morbidity were 1.9% and 3.8% at 1 month, respectively, and 4.4% and 1.9% at 12 months, respectively. One-month morbidity (P = .02) and mortality (P = .003) were higher in the ruptured group (10.0% and 8.0%, respectively) compared with unruptured-recurrent group (1.9% and 0.0%, respectively). Overall adequate occlusion (complete occlusion and neck remnant) was 86.3%. The percentage of adequate occlusion... Continued on ES/IODE ➡️ https://etcse.fr/ZMOGt ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Aneurysm Treatment with Woven EndoBridge-17: Angiographic and Clinical Results at 12 Months from a Retrospective, 2-Center Series Abstract: BACKGROUND AND PURPOSE: This retrospective, 2-center study investigated the feasibility, safety, and efficacy at 12-month follow-up of the treatment of ruptured, unruptured, and recurrent intracranial aneurysms using the latest generation of the Woven EndoBridge (WEB) device, the WEB-17 system. MATERIALS AND METHODS: Aneurysms treated with WEB-17 were extracted from the databases of 2 neurovascular centers. Patients, aneurysm characteristics, complications, and clinical and anatomic results were analyzed. RESULTS: From February 2017 to May 2021, two hundred twelve patients with 233 aneurysms (181/233, 77.7%, unruptured-recurrent, and 52/233, 22.3%, ruptured) were included. High treatment feasibility (95.3%) was reported and was similar in ruptured aneurysms (94.2%) and unruptured-recurrent aneurysms (95.6%) (P = .71) and in typical (95.4%) and atypical (94.7%) locations (P = .70), but it was lower in aneurysms with an angle between the parent artery and main aneurysm axis of ≥45° (90.2%) compared with those with an angle of <45° (97.1%) (P = .03). Global mortality and morbidity were 1.9% and 3.8% at 1 month, respectively, and 4.4% and 1.9% at 12 months, respectively. One-month morbidity (P = .02) and mortality (P = .003) were higher in the ruptured group (10.0% and 8.0%, respectively) compared with unruptured-recurrent group (1.9% and 0.0%, respectively). Overall adequate occlusion (complete occlusion and neck remnant) was 86.3%. The percentage of adequate occlusion... Continued on ES/IODE ➡️ https://etcse.fr/ZMOGt ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

📃Scientific paper: Iliac vein variation in the sacral promontory on three-dimensional computed tomography angiography: a prospective observational study before laparoscopic sacrocolpopexy Abstract: Introduction and Hypothesis Venous injury may occur during exposure of the anterior longitudinal ligament at the anterior sacral promontory (SP). We aimed to quantitatively measure the extent of the vascular window (VW) in front of the SP in patients with internal iliac vein (IIV) variations using preoperative three-dimensional computed tomography angiography (3DCTA). We hypothesized that patients with IIV variations would have a narrow VW. Methods This prospective observational study included patients scheduled for laparoscopic sacrocolpopexy (LSC) between July 2022 and April 2023 who underwent preoperative 3DCTA. The primary endpoint was the VW measurement in the standard and variant IIV groups using 3DCTA before LSC. The secondary endpoint was the difference between the two IIV groups adjusted for age, body mass index, hypertension, and diabetes using an analysis of covariance (ANCOVA) model. Multiple regression analysis was performed to analyze the effect of factors on the distance from the SP to great vascular bifurcations. Results There were 20 cases of IIV variation (20.2%). VW was 28.8 ± 12.4 mm in the variant group and 39.6 ± 12.6 mm in the standard group ( p = 0.001). In the ANCOVA model, IIV variations affected VW (coefficient, –11.8; 95% confidence interval [CI], –18.4 to –5.08, p < 0.001). Multivariate analysis revealed that the aorta–SP distance decreased with age (coefficient, −0.44; 95% CI, −0.77 to −0.11, p = 0.009). Conclusions One in five women... Continued on ES/IODE ➡️ https://etcse.fr/a0Uy3 ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

🎉 Excited to share our recent publication in the Hellenic Society of Cardiology: "Association of Neutrophil Extracellular Traps (NETs) Burden with Clinical and Angiographic Characteristics in Patients with ST-Elevation Myocardial Infarction." 🔬 Our study reveals key insights into the role of NETs in STEMI patients, linking NETs burden with both clinical outcomes and angiographic features. These findings could open new avenues for understanding cardiovascular inflammation and improving patient care. Read more about our research in the Hellenic Society of Cardiology journal! #Cardiology #STEMI #CardiovascularResearch #Neutrophils #Inflammation #Research